Skip to main content
OpenTrials
Completed

NCT Number: NCT04066036

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa

This is a prospective observational cohort study enrolling participants in South Africa and Uganda who are prescribed an HIV treatment regimen containing lamivudine, tenofovir, and dolutegravir, which is known as TLD. We hope to better understand how effective TLD will be in sub-Saharan Africa. If treatment failure occurs, we seek to understand the possible reasons, including drug resistance and adherence challenges.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Africa Health Research Institute, Somkele, KwaZulu-Natal, South Africa

Loading trial locations.

About this study

This study is a prospective observational cohort study at three government-supported HIV clinics in rural South Africa and Uganda. We will enroll 1,000 adults living with HIV who are switched from first-line antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) to TLD. We will follow participants for one year with study visits at enrollment, 24 weeks, and 48 weeks. Study procedures include interviews, body measurements, chart review, and collection of blood and urine specimens for retrospective testing, including viral load, drug resistance testing, antiretroviral drug level testing, and tests to evaluate the effects of TLD on renal, liver, metabolic, and other organ function.

Aim 1: To determine the contributions of resistance prior to switch to TLD from a NNRTI-based regimen to risk of treatment failure after six and twelve months on TLD. Hypothesis: People living with HIV who experience virologic failure on TLD will have increased odds of NRTI mutations prior to TLD exposure, compared to controls with virologic suppression.

Aim 2: Explore pharmacologic measures of adherence to distinguish virologic failure on TLD due to suboptimal adherence versus resistance using 2a) urine tenofovir (TFV) levels and 2b) tenofovir diphosphate (TFV-DP) in dried blood spots (DBS). Hypothesis: Absence of TFV in urine and TFV-DP concentrations in DBS will distinguish ART failure with versus without resistance.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • HIV-positive and in care at one of the study clinics
  • Current use of NNRTI-based, first-line ART for a minimum of 6 months
  • Prescribed change to TLD by clinic staff
  • Residing within 100 kilometers of the treatment clinic without plans to change permanent residence in the next 48 weeks
  • Consents to participation

Exclusion criteria

There are no specific exclusion criteria. Both men and women will be theoretically eligible. We note that decision to use TLD in patients at the recruitment clinic will be made by clinic staff, and referral for study procedures will not be made until after this decision is made. We also note that, as of the time of this protocol draft, TLD use might be limited to men, women of non-child bearing ages, and women confirmed to be on contraception. This study will follow both national guidelines and clinician discretion about use of TLD in the clinic population.

Treatment and study plan

This is an observational study only.

Other

This is an observational study only.

Primary outcomes

  1. Proportion of participants with virologic failure (HIV-1 RNA >= 200 copies/mL)

    Time frame: 48 weeks

    HIV-1 RNA >= 200 copies/mL

Secondary outcomes

  1. Proportion of participants with virologic failure (HIV-1 RNA >= 1,000 copies/mL)

    Time frame: 48 weeks

    HIV-1 RNA >= 1,000 copies/mL

  2. Proportion of participants with HIV drug resistance

    Time frame: 24 and 48 weeks

    Proportion of participants with International AIDS Society-defined drug resistance mutations to their current regimen

Sponsors and collaborators

Lead sponsor

Massachusetts General Hospital

Other

Collaborators

  • Africa Health Research Institute
  • Emory University
  • Harvard Medical School (HMS and HSDM)
  • Mbarara University of Science and Technology
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • University of KwaZulu
  • ViiV Healthcare
  • Wellcome Trust

Registry information

Official study title

Population Effectiveness of Dolutegravir Implementation in Sub-Saharan Africa: A Prospective Observational Cohort Study

Acronym: DISCO

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Aug 22, 2019
Registry last updated
Oct 23, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.